Dan Beraha, M.D. v. Baxter Health Care Corporation

956 F.2d 1436, 1992 WL 48585
CourtCourt of Appeals for the Seventh Circuit
DecidedApril 28, 1992
Docket90-3789
StatusPublished
Cited by218 cases

This text of 956 F.2d 1436 (Dan Beraha, M.D. v. Baxter Health Care Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dan Beraha, M.D. v. Baxter Health Care Corporation, 956 F.2d 1436, 1992 WL 48585 (7th Cir. 1992).

Opinion

MANION, Circuit Judge.

Invoking the diversity jurisdiction of the federal court, Dan Beraha, M.D., filed suit against Baxter Health Care Corporation (“Baxter”) based on an exclusive patent license agreement (“license agreement”) between Beraha and Omnis Surgical, Inc. (“Omnis”), a Baxter affiliate that was later merged into Baxter. 1 Count I of the Complaint claimed that Baxter violated express and implied obligations of good faith and fair dealing in the license agreement; Count II claimed that Baxter breached a fiduciary obligation under the license agreement; and Count III alleged that Baxter made false representations to Ber-aha at the time of the license agreement. The district court issued summary judgment in favor of Baxter on all three counts. Beraha appeals, however, only from the district court’s summary judgment on Counts I and III. We affirm in part, vacate in part and remand the case to the district court for further proceedings.

I. Background

A license agreement for the development of a biopsy needle lies at the center of this controversy. Baxter makes and sells a variety of medical products, including a needle for performing prostate biopsies known as the Tru-Cut needle. In 1983, Beraha, a physician specializing in urology, designed a biopsy needle that he believed was an improvement over the Tru-Cut biopsy needle. In February 1984, Beraha filed an application to patent his improvement. 2 In April and May of 1984, Beraha negotiated with Baxter for the grant of a license under the patent application and any resulting patent. At the time of these negotiations, Beraha had not made or tested the biopsy needle claimed in his patent application.

During initial negotiations with Baxter, Beraha sought the advice of his patent attorney, Macdonald Wiggins. In a letter to Michael Cannizzaro, Vice President for Sales & Marketing at Omnis, dated April 20, 1984, Wiggins stated that he had reviewed the terms Baxter had proposed to Beraha for rights to Beraha’s invention. Wiggins then listed for Cannizzaro the recommendations that he made to Beraha. Under those recommendations, Baxter would receive an exclusive license to manufacture and sell Beraha’s invention worldwide. Baxter would pay Beraha a royalty of $1.00 on each unit sold during the pend-ency of the application and for the term of any patent that eventually issued from the application. If the application for the patent were rejected, the royalty would be reduced to 50 cents on each unit for a period of ten years, and Baxter would have a royalty-free license thereafter. Baxter would pay Beraha an advance royalty of $50,000 when the license agreement was executed. After the first anniversary of the license agreement, Baxter would guarantee Beraha a minimum annual royalty of $50,000. As an alternative to a license agreement, Wiggins suggested an agree *1438 ment in which Beraha would assign all rights in the invention and any patent issuing on the invention. Under the assignment agreement, Beraha would receive a downpayment of $100,000, annual payments of $50,000 for ten years, and royalties of 25 cents per unit sold for the life of the patent or 12.5 cents per unit sold for ten years after a final rejection of the patent.

On May 1, 1984, Paul Flattery, Associate General Counsel for Baxter, sent Beraha a patent license agreement counter-proposal that Cannizzaro wanted to discuss with Beraha at a meeting in New Orleans. The letter accompanying the counter-proposal stated that Cannizzaro wanted to deal directly with Beraha regarding the financial terms of the license agreement but that if Beraha had any other questions regarding the license agreement, Flattery would work with Beraha’s attorney to resolve them pri- or to the meeting. Under the counter-proposal, Baxter would acquire an exclusive license. Beraha would receive an advance royalty payment of $20,000, an earned royalty of three percent of net sales and a guaranteed minimum annual royalty of $10,000 after the first anniversary of the license agreement. If no patent issued before the third anniversary of the license agreement, no further earned royalties would be due. The counter-proposal limited the total royalties over the life of the license agreement to $500,000. It further provided that Baxter could convert the license to a nonexclusive license by written notice to Beraha at any time after the third anniversary of the license agreement and cease minimum annual royalty obligations. If Beraha subsequently granted a license under the licensed patent at a royalty rate less than that paid by Baxter, then Baxter would be entitled to reduce its royalty to the rate charged to the other licensee. Baxter could terminate the license at any time upon ninety days written notice to Beraha.

On May 8, 1984, at Cannizzaro’s request, Beraha met with Victor Chaltiel, president of Omnis, and Cannizzaro in New Orleans to negotiate the terms of the license agreement. No attorneys were present at the meeting. The discussions focused on the Baxter counter-proposal. Chaltiel and Ber-aha went through the counter-proposal paragraph by paragraph, making changes and initialling them.

At the end of the meeting, the parties had a marked-up copy of the counter-proposal that increased the advance royalty from $20,000 to $50,000, deleted the provision for minimum annual royalties, and deleted the cap on total royalties that would be paid to Beraha. The royalty rate was increased from three percent to three and one-half percent, and the time period during which royalties would be paid even if no patent issued was extended from three to four years. The agreement deleted Baxter’s option to convert the license to a nonexclusive license and terminate the license upon written notice. The increase in the advance royalty from $20,000 to $50,000 served as a trade-off against minimum annual royalties. While Chaltiel gave some oral assurance to Beraha at some point in their negotiations that Baxter would go forward with the Beraha needle, 3 no best efforts provision was written onto the marked-up counter-proposal during the May 8 meeting. Furthermore, the parties left intact a merger clause stating that the agreement constituted the entire understanding between the parties. Beraha and Chaltiel, on behalf of Baxter, then signed the marked-up counter-proposal.

On May 24, 1984, Paul Flattery sent a letter to Beraha with an attached license agreement. The license agreement incorporated all the handwritten changes that Beraha and Chaltiel had made and initialled on the Baxter counter-proposal at the New Orleans meeting on May 8, 1984. At first Beraha refused to sign the re-typed version of the agreement because it contained no *1439 best efforts provision. He telephoned his contacts at Baxter 4 and requested some assurance from Chaltiel concerning the level of effort that Baxter would exert to develop the Beraha needle. During the telephone conversation, Beraha received no representation concerning the specific level of effort that would be made. Nevertheless, reassured by the promise that Chaltiel would send him a letter, on May 29, 1984, Beraha signed the re-typed version of the agreement which did not contain a best efforts clause. Flattery suggested language to Chaltiel to be used in a letter to Beraha.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kyle-Wolf v. McClure
C.D. Illinois, 2021
Gerald Deom v. Walgreen Company
591 F. App'x 313 (Sixth Circuit, 2014)
RBS Citizens, N.A. v. Sanyou Import, Incorporated
525 F. App'x 495 (Seventh Circuit, 2013)
Grabianski v. Bally Total Fitness Holding Corp.
891 F. Supp. 2d 1036 (N.D. Illinois, 2012)
Schilke v. Wachovia Mortgage, FSB
758 F. Supp. 2d 549 (N.D. Illinois, 2010)
DERMESROPIAN v. Dental Experts, LLC
718 F. Supp. 2d 143 (D. Massachusetts, 2010)
MacOn County Greyhound Park, Inc. v. Knowles
39 So. 3d 100 (Supreme Court of Alabama, 2009)
Hall v. Martin Engineering Co.
597 F. Supp. 2d 651 (S.D. West Virginia, 2009)
LaSalle Bank Nat'l Assoc. v. Paramont Properties
588 F. Supp. 2d 840 (N.D. Illinois, 2008)
Cox v. Hartshorn
503 F. Supp. 2d 1078 (C.D. Illinois, 2007)
Boyer v. Gildea
374 B.R. 645 (N.D. Indiana, 2007)
LaSalle Bank National Ass'n v. Moran Foods, Inc.
477 F. Supp. 2d 932 (N.D. Illinois, 2007)
Cirilla v. Kankakee County Jail
438 F. Supp. 2d 937 (C.D. Illinois, 2006)
Miller v. Javitch, Block & Rathbone, LLP
397 F. Supp. 2d 991 (N.D. Indiana, 2005)
Gentieu v. Tony Stone Images/Chicago, Inc.
255 F. Supp. 2d 838 (N.D. Illinois, 2003)
Hale v. Scott
252 F. Supp. 2d 728 (C.D. Illinois, 2003)
Schele v. Porter Memorial Hospital
198 F. Supp. 2d 979 (N.D. Indiana, 2001)
Lenzo v. School City of East Chicago
140 F. Supp. 2d 947 (N.D. Indiana, 2001)
Kinesoft Development Corp. v. Softbank Holdings Inc.
139 F. Supp. 2d 869 (N.D. Illinois, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
956 F.2d 1436, 1992 WL 48585, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dan-beraha-md-v-baxter-health-care-corporation-ca7-1992.